96 related articles for article (PubMed ID: 1583339)
1. Lack of activity of amphotericin B in systemic murine fusarial infection.
Anaissie EJ; Hachem R; Legrand C; Legenne P; Nelson P; Bodey GP
J Infect Dis; 1992 Jun; 165(6):1155-7. PubMed ID: 1583339
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy in treatment of murine infection by Fusarium solani.
Ruíz-Cendoya M; Mariné M; Guarro J
J Antimicrob Chemother; 2008 Sep; 62(3):543-6. PubMed ID: 18495651
[TBL] [Abstract][Full Text] [Related]
3. Treatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinafine.
Ruíz-Cendoya M; Pastor FJ; Capilla J; Guarro J
Int J Antimicrob Agents; 2011 Jan; 37(1):58-61. PubMed ID: 20947310
[TBL] [Abstract][Full Text] [Related]
4. Tolerance to amphotericin B in clinical isolates of Candida tropicalis.
Barchiesi F; Maracci M; Baldassarri I; Spreghini E; Giannini D; Scalise G
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):179-85. PubMed ID: 15541603
[TBL] [Abstract][Full Text] [Related]
5. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis.
Warn PA; Sharp A; Morrissey G; Denning DW
J Antimicrob Chemother; 2005 Sep; 56(3):590-3. PubMed ID: 16046462
[TBL] [Abstract][Full Text] [Related]
6. Treating disseminated fusariosis: amphotericin B, voriconazole or both?
Ho DY; Lee JD; Rosso F; Montoya JG
Mycoses; 2007 May; 50(3):227-31. PubMed ID: 17472622
[TBL] [Abstract][Full Text] [Related]
7. Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani.
Roilides E; Lyman CA; Armstrong D; Stergiopoulou T; Petraitiene R; Walsh TJ
Mycoses; 2006 Mar; 49(2):109-13. PubMed ID: 16466443
[TBL] [Abstract][Full Text] [Related]
8. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
Li L; Wang Z; Li R; Luo S; Sun X
Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani.
Guarro J; Pujol I; Mayayo E
Antimicrob Agents Chemother; 1999 May; 43(5):1256-7. PubMed ID: 10223945
[TBL] [Abstract][Full Text] [Related]
11. Fusarium infection after solid-organ transplantation.
Sampathkumar P; Paya CV
Clin Infect Dis; 2001 Apr; 32(8):1237-40. PubMed ID: 11283817
[TBL] [Abstract][Full Text] [Related]
12. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
Consigny S; Dhedin N; Datry A; Choquet S; Leblond V; Chosidow O
Clin Infect Dis; 2003 Jul; 37(2):311-3. PubMed ID: 12856225
[TBL] [Abstract][Full Text] [Related]
13. [Resolution of a disseminated infection by Fusarium solani in a patient with acute promyelocytic leukemia and granulocytopenia secondary to chemotherapy by the combined use of G-CSF and liposomal amphotericin B].
Sancho JM; Ribera JM; Matas L; Batlle M
Med Clin (Barc); 1997 Jun; 109(4):156-7. PubMed ID: 9289532
[No Abstract] [Full Text] [Related]
14. Evaluation of the inhibitory effect of amphotericin B on the apical growth of F. solani using the BioCell-Tracer system.
Teixeira AB; Moretti ML; Machado HC; Nishimura K; Taguchi H; Schreiber AZ
Mycoses; 2007 May; 50(3):183-8. PubMed ID: 17472613
[TBL] [Abstract][Full Text] [Related]
15. A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B.
Capilla J; Mayayo E; Serena C; Pastor FJ; Guarro J
J Antimicrob Chemother; 2004 Dec; 54(6):1092-5. PubMed ID: 15509616
[TBL] [Abstract][Full Text] [Related]
16. [New aspects in treatment of systemic mycoses].
Presterl E; Graninger W
Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
[TBL] [Abstract][Full Text] [Related]
17. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
18. Pathogenicity of Trichosporon asahii in a murine model of disseminated trichosporonosis.
Yang RY; Wang WL; Ao JH; Hao ZF; Zhang J; Wang CM
Chin Med J (Engl); 2008 Dec; 121(24):2557-60. PubMed ID: 19187595
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B.
Rothe A; Seibold M; Hoppe T; Seifert H; Engert A; Caspar C; Karthaus M; Fätkenheuer G; Bethe U; Tintelnot K; Cornely OA
Ann Hematol; 2004 Jun; 83(6):394-7. PubMed ID: 14648020
[TBL] [Abstract][Full Text] [Related]
20. Fusarium verticillioides abscess of the nasal septum in an immunosuppressed child: case report and identification of the morphologically atypical fungal strain.
Dornbusch HJ; Buzina W; Summerbell RC; Lass-Flörl C; Lackner H; Schwinger W; Sovinz P; Urban C
J Clin Microbiol; 2005 Apr; 43(4):1998-2001. PubMed ID: 15815043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
